Treatment-emergent mutations in myelodysplastic syndrome with del(5q) - lenalidomide related or disease-intrinsic clonal evolution?

被引：1
|
作者：
Abdallah, Mostafa [1 ]
Reichard, Kaaren [1 ]
Gangat, Naseema [1 ]
Tefferi, Ayalew [1 ]
机构：
[1] Mayo Clin, Rochester, MN 55905 USA
来源：
BLOOD CANCER JOURNAL | 2024年 / 14卷 / 01期
关键词：
TP53; MUTATIONS; PREVALENCE;
D O I：
10.1038/s41408-024-01027-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Treatment-emergent mutations in myelodysplastic syndrome with del(5q) – lenalidomide related or disease-intrinsic clonal evolution?
    Mostafa Abdallah
    Kaaren Reichard
    Naseema Gangat
    Ayalew Tefferi
    Blood Cancer Journal, 14
  • [2] MYELODYSPLASTIC SYNDROME WITH DEL(5Q) AND LENALIDOMIDE
    Gritsaev, S. V.
    Martinkevitch, I. S.
    Petrova, E. V.
    GEMATOLOGIYA I TRANSFUZIOLOGIYA, 2013, 58 (02): : 3 - 10
  • [3] Unusual clonal evolution involving 5q in a case of myelodysplastic syndrome with deletion 5q 31 treated with lenalidomide
    Eclache, Virginie
    Da Rocha, Anna
    Le Roux, Genevieve
    Fenaux, Pierre
    HAEMATOLOGICA, 2008, 93 (02) : 315 - 316
  • [4] Lenalidomide for del(5q) and Non-del(5q) Myelodysplastic Syndromes
    Giagounidis, Aristoteles A. N.
    SEMINARS IN HEMATOLOGY, 2012, 49 (04) : 312 - 322
  • [5] MYELODYSPLASTIC SYNDROME WITH DEL(5Q): ROUTES OF CLONAL EVOLUTION INTO AML WITH COMPLEX KARYOTYPES
    Goehring, Gudrun
    Feurstein, Simone
    Hofmann, Winfried
    Ganser, Arnold
    Kreipe, Hans
    Schlegelberger, Brigitte
    ANNALS OF HEMATOLOGY, 2013, 92 : S8 - S8
  • [6] Routes of clonal evolution into complex karyotypes in myelodysplastic syndrome patients with del(5q)
    Goehring, G.
    Feurstein, S.
    Thomay, K.
    Hofmann, W.
    Ganser, A.
    Kreipe, H.
    Schlegelberger, B.
    LEUKEMIA RESEARCH, 2013, 37 : S136 - S136
  • [7] Mechanisms of Resistance to Lenalidomide in Del(5q) Myelodysplastic Syndrome Patients
    Martinez-Hoyer, Sergio
    Docking, Rod
    Chan, Simon
    Jadersten, Martin
    Parker, Jeremy
    Karsan, Aly
    BLOOD, 2015, 126 (23)
  • [8] Telomere shortening, clonal evolution and disease progression in myelodysplastic syndrome patients with 5q deletion treated with lenalidomide
    G Göhring
    K Lange
    W Hofmann
    K V Nielsen
    E Hellström-Lindberg
    L Roy
    M Morgan
    H Kreipe
    G Büsche
    A Giagounidis
    B Schlegelberger
    Leukemia, 2012, 26 : 356 - 358
  • [9] Telomere shortening, clonal evolution and disease progression in myelodysplastic syndrome patients with 5q deletion treated with lenalidomide
    Goehring, G.
    Lange, K.
    Hofmann, W.
    Nielsen, K. V.
    Hellstrom-Lindberg, E.
    Roy, L.
    Morgan, M.
    Kreipe, H.
    Buesche, G.
    Giagounidis, A.
    Schlegelberger, B.
    LEUKEMIA, 2012, 26 (02) : 356 - 358
  • [10] Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations
    Mallo, Mar
    del Rey, Monica
    Ibanez, Mariam
    Jose Calasanz, Ma
    Arenillas, Leonor
    Jose Larrayoz, Ma
    Pedro, Carmen
    Jerez, Andres
    Maciejewski, Jaroslaw
    Costa, Dolors
    Nomdedeu, Meritxell
    Diez-Campelo, Maria
    Lumbreras, Eva
    Gonzalez-Martinez, Teresa
    Marugan, Isabel
    Such, Esperanza
    Cervera, Jose
    Cigudosa, Juan C.
    Alvarez, Sara
    Florensa, Lourdes
    Hernandez, Jesus Ma
    Sole, Francesc
    BRITISH JOURNAL OF HAEMATOLOGY, 2013, 162 (01) : 74 - 86
12345